AsianScientist (Aug. 30, 2016) – Non-invasive genetic testing company Singlera Genomics has announced it has successfully raised US$20 million in Series A financing. The financing round was led by Lilly Asia Ventures, together with Green Pine Capital Partners, CDBI Partners and others.
Based in La Jolla, California in the US and Shanghai, China, Singlera has proprietary technologies in single cell sequencing, DNA methylation and bioinformatics. The company’s main products and services include tumor diagnosis, personalized treatment and non-invasive prenatal diagnosis.
The Series A round will help Singlera expand the development and commercialization of its non-invasive genomic sequencing tests for cancer and other genetic diseases. It will also use the funds to further expand its R&D operations and expedite the launch of new product lines.
Professor Gao Yuan, chairman of Singlera Genomics, said, “Singlera’s non-invasive genomic sequencing diagnostic technologies could significantly enhance the accuracy of tumor diagnosis and provide powerful guidance for new treatments.”
———
Source: Singlera Genomics Inc..
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
